Sanofi announced a leadership overhaul after its board decided not to renew the mandate of CEO Paul Hudson, effective immediately. The French pharmaceutical giant named Garijo, currently head of Merck KGaA’s pharmaceutical division, as his successor. This move comes amid strategic shifts in Sanofi’s oncology and vaccine portfolios, with Garijo’s appointment signaling a focus on accelerating drug development pipelines. The board emphasized the need for fresh leadership to navigate regulatory challenges and competitive pressures in the global biopharma sector.

Hudson, who led Sanofi since 2018, oversaw the company’s $9.5 billion acquisition of Translate Bio and expanded its rare disease treatments. His departure follows speculation about internal disagreements over prioritizing late-stage clinical trials for key drugs like Dupixent. Garijo, a 15-year Sanofi veteran previously holding senior roles in R&D, brings expertise in managing complex drug approvals and partnerships, including Merck’s collaborations with Pfizer on mRNA vaccine technology.

Analysts suggest the transition reflects Sanofi’s pivot toward personalized medicine and mRNA platforms. Garijo’s background in oncology R&D aligns with the company’s push to expand its cell therapy offerings, which saw a 22% revenue surge in 2023. The appointment also positions Sanofi to strengthen ties with Merck KGaA, a key player in advanced therapies, potentially unlocking synergies in shared research initiatives.

Market reactions were mixed, with Sanofi’s shares rising 1.2% on the news. Investors highlighted Garijo’s track record of scaling biotech ventures, though questions remain about how swiftly he can address Hudson’s legacy of delayed drug launches. The shakeup underscores intensifying competition in the $1.5 trillion pharmaceutical market, where leadership agility is critical to maintaining growth amid patent expirations and generic competition.